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Abstract
Background: Case reports have linked adult hypophosphatasia as a possible cause of atypical femur fractures (AFF)
associated with bisphosphonate use. Adult hypophosphatasia is an asymptomatic genetic condition which results
in low alkaline phosphatase and elevated pyridoxal phosphate. We conducted a case–control study to assess the
role of hypophosphatasia and atypical femur fracture.
Methods: We recruited 13 control patients who took long term bisphosphonates without complication and 10
patients who sustained atypical femur fractures (mean bisphosphonate use, 9 years both cohorts). Patients
underwent clinical exam and measurement of alkaline phosphatase and pyridoxal phosphate (PLP) levels. In
addition, DNA was extracted and the ALPL gene was sequenced in both cohorts.
Results: Low alkaline phosphatase levels (<55 U/L) were seen in 5/10 AFF patients and 5/13 control patients. Two
control patients demonstrated low alkaline phosphatase levels and elevated PLP. The alkaline phosphatase (ALPL)
gene exons and intron splice sites were sequenced in the atypical femur fracture and control cohorts and no
coding mutations were identified in any subjects. Atypical femur fracture patients demonstrated more varus hip
alignment (p < 0.048) with no significant difference in mechanical axis.
Conclusions: We found no evidence of hypophosphatasia as a risk factor for atypical femur fractures. Laboratory
findings of mildly low alkaline phosphatase activity were equally common in atypical and control cohorts and may
be due to long term bisphosphonate use.
Trial registration: Clinicaltrials.gov number NCT01360099. Prospectively registered May 20, 2011. First patient
enrolled June 14, 2011.
Background
Patients who take bisphosphonate medications long-
term are at increased risk for atypical femur fractures
[1]. The fractures are characterized by low energy
injuries, prodromal pain, frequent bilaterally, and radio-
graphic hallmarks of transverse orientation, minimal
comminution, and lateral beaking [2]. There is a growing
consensus that atypical femur fractures are due to long-
term bisphosphonate medications causing suppressed
bone turnover which results in inability of bone to
repair microfractures [3] Varus hip geometry may
increase the strain seen on the lateral cortex and increase
the risk [4, 5]. However the vast majority of patients who
take bisphosphonates experience a reduction in hip frac-
ture risk and never experience an atypical femur fracture
[6, 7] or show radiographic signs of an impending fracture
even with 10 or more years of use [8]. The rarity of atyp-
ical femur fractures among bisphosphonate users suggests
that certain people have an undiagnosed risk factor that
predisposes them to atypical femur fracture when they are
exposed to bisphosphonates.
Whyte [9] and Lane [10] have proposed an intriguing
hypothesis that adult hypophosphatasia may be a risk
factor for AFF. Hypophosphatasia is a generally asymp-
tomatic genetic condition with low alkaline phosphatase
activity seen in up to 5 % of adults. Clinical features
include propensity to fracture, early loss of deciduous
teeth, and pain. The disease is caused by mutations in
the tissue non-specific alkaline phosphatase gene
(TNSALP, current gene symbol, ALPL). The low alkaline
phosphatase activity results in a buildup of pyridoxal 5′
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phosphate (PLP) and inorganic pyrophosphate. Inorganic
pyrophosphate is chemically similar to bisphosphonates
and also inhibits bone mineralization. Patients with
severe hypophosphatasia are known to sustain subtro-
chanteric fractures of the femur, and there has been a
case report of atypical femur fracture in a patient with
hypophosphatasia taking bisphosphonates [9].
We conducted a retrospective case–control study to
test whether hypophosphatasia is a risk factor for atyp-
ical femur fracture.
Methods
After IRB approval, we recruited from the community a
cohort of patients who had sustained atypical femur
fractures while taking bisphosphonates, and a control
cohort of patients who had taken bisphosphonates for at
least 5 years and not sustained a femur fracture. For the
fracture cohort, we worked from a list of patients who
had been referred to us after atypical femur fracture.
Fourteen fracture patients were telephoned to participate
in the study, and 4 declined. For the control cohort, we
recruited patients who had previously enrolled in a
longitudinal study of bisphosphonate users [8]. Thirteen
patients were telephoned and 13 agreed.
Patients underwent a standardized history (including
fracture history and dental history), a physical exam and
standing long leg radiographs. Fasting blood was drawn
and tested for alkaline phosphatase and PLP levels. The
blood tests were performed at Mayo Medical Laboratories.
Patients withheld vitamin supplementation for at least
1 week prior to testing because vitamin B ingestion can
alter testing for PLP. In hypophosphatasia, alkaline phos-
phatase is low or low normal and PLP is elevated. Blood
was drawn and DNA extracted for focused sequencing of
the ALPL gene. Sequencing included the exons, part of
the promoter, and the splice sites. We did not sequence
the introns. Due to the cost of sequencing, we tested all of
the atypical femur fracture patients, but only sequenced in
the nine controls who manifested laboratory evidence of
low or low normal alkaline phosphatase (below 60 ng/dl).
Statistical testing was done using Microsoft Excel and
SPSS 10.0. Continuous variables were compared using
the student’s t-test while chi-squared testing was per-
formed for categorical variables. A post hoc power ana-
lysis was performed to assess the risk of type II error.
Results
The cohort included ten atypical femur fracture patients
and 13 asymptomatic controls. Age and gender dis-
tribution were similar in each cohort (Table 1). No pa-
tients described dental abnormalities such as early loss of
deciduous teeth. All atypical femur fracture patients had
sustained complete fractures and underwent intramedul-
lary nailing. Atypical femur fracture patients had stopped
taking bisphosphonates an average of 3.6 years. One pa-
tient in the fracture group and two in the control group
were taking diuretics. The atypical group met at least four
of the major diagnostic criteria (as required by ASBMR to
meet the case definition) and zero to three of the minor
diagnostic criteria [2].
Alkaline phosphatase levels were low in five of ten
atypical femur fracture patients and were low in a five of
13 controls (p = 0.58). In the patients with low alkaline
phosphatase levels, the confirmatory PLP test was ele-
vated in only two control patients; both patients had a
history of taking multivitamins regularly.
Genetic sequencing of the ALPL gene in patients with
AFF and controls with low alkaline phosphatase showed
no abnormalities which would have resulted in hypopho-
sphatasia. We found only single nucleotide polymorphisms




Number of patients 10 13
Mean age in years (range) 71 (68–79) 68 (62–84) 0.27
Female (%) 9/10 (90 %) 10/13 (77 %) 0.45
Bisphosphonate used
Alendronate 7 (70 %) 10 (77 %) 0.68
Ibandronate 2 (20 %) 3 (23 %)
Risendronate 1 (10 %) 0
Proportion of patients with
Vitamin D supplementation (%)












58 (37–73) 56 (38–74) 0.81
Proportion of patients with
abnormal alkaline
phosphatase (below 50 U/L)




29.8 (5–44) 20.6 (5–118) 0.37
Mean neck-shaft
angle degrees (S.D.)
132 (3.1) 136 (5.2) 0.048
Mechanical axis angle
degreesb (S.D.)
−0.71 (5.0) −0.15 (2.7) 0.76
Lateral distal femoral
angle degrees (S.D.)
90.7 (5.0) 90.2 (2.7) 0.76
a10 of the thirteen patients had discontinued bisphosphonates. Three
were continuing
bA positive number represents valgus alignment
cNormal range 55 to 105 U/L
dNormal range 5 to 50 mcg/L
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(SNPs) which are common variants in the population, and
would not result in deleterious missense or nonsense mu-
tation (Table 2). Polymorphisms were found equally in
controls and atypical femur patients.
Review of standing long leg radiographs showed that
atypical femur fracture patients had more varus hip
geometry with a higher mean neck shaft angle than con-
trols (136° versus 132°, p < 0.05). However this did not
result in a difference in overall mechanical axis. The
lateral distal femoral angle (normally 87°) was a mean of
90.7° in the atypical femur fracture cohort and 90.2° in
the control cohorts (p = 0.70).
Discussion
We found that patients who sustained an atypical femur
fracture did not have laboratory findings or genetic mu-
tations consistent with hypophosphatasia.
The initial case reports of atypical femur fractures re-
sulted in numerous investigations. Several epidemiologic
studies have documented the clear association between
bisphosphonate use and atypical femur fracture [11, 12].
When the drug is withdrawn, the risk of fracture drops
rapidly [13]. There is evidence of a dose response rela-
tionship [14]. Finally there is evidence that other bone
anti-resorptive medications can produce atypical femur
fractures [15].
However, the evidence indicates that bisphosphonate
medications are the best first line treatment for osteo-
porosis, and are safe. Atypical femur fractures are rare,
affecting one in 50,000 bisphosphonate users, and the
fracture is readily treatable [9]. Furthermore, now that
symptoms of prodromal thigh pain are recognized and
the duration of treatment is being re-evaluated, the inci-
dence of atypical femur fracture may be decreasing [16].
If the risk factors for atypical femur fracture could be
elucidated, better targeting may eliminate atypical femur
fractures entirely.
We investigated one proposed genetic risk factor for
atypical femur fracture and found no mutations in the al-
kaline phosphatase gene. The hypophosphatasia hypoth-
esis is intellectually attractive in that patients with severe
hypophosphatasia are known to experience subtrochan-
teric femur fractures which are radiographically similar to
atypical femur fracture, one case report suggests the
possibility, and there is biological plausibility. However
our data clearly demonstrate an absence of disease causing
mutations in the ALPL gene. The low alkaline phosphat-
ase levels we observed in nearly 50 % of AFF cases and
non-AFF controls may simply be due to bisphosphonate
treatment [17]. While many patients had discontinued
medications, it well known that the half-life of bispho-
sphonates is almost 10 years, so prolonged effects are not
unexpected [18].
It is possible that other genetic abnormalities predispose
patients to atypical femur fracture. For example, a muta-
tion in the genes for type I collagen may play a role be-
cause the fractures are on the tensile side of the femur. A
logical approach to evaluate the genetic hypothesis would
be to perform a genome-wide association study. However,
in the absence of one or more variants with large effect
size, a typical genome-wide association study requires
about 1000 patients and a similar number of controls.
The main limitation of this study is the risk of Type II
error. With a small sample size, there remains the possibil-
ity that an association between ALPL mutations exists but
we did not detect it due to chance. A post hoc power ana-
lysis reveals that our study has 80 % power to detect a 40 %
prevalence of ALPL mutations in atypical fracture patients.
In other words, if the ALPL mutations were ten times more
common (or higher) in atypical femur fracture patients,
80 % of studies of this size would detect a difference.
Conclusions
We did not find laboratory or genetic evidence for hypo-
phosphatasia in patients with atypical femur fracture.
Further studies to define the biological risk factors for
atypical femur fracture are warranted.
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Table 2 Coding variants of the ALPL gene found in atypical fracture (AFF) patients and controls
Variant ID cDNA variant Protein variant Variant allele frequency
in AFF patients (n = 10)
Variant allele frequency
in controls (n = 9)
Variant allele frequency
in ESP-EAa
rs1780316 c.330 T > C p.S110S 1.00 0.94 0.95
rs3200254 c.787 T > C p.Y263H 0.20 0.17 0.11
rs3200255 c.876A > G p.P292P 0.20 0.17 0.11
rs34605986 c.1565 T > C p.V522A 0.10 0.00 0.10
aESP-EA NHLBI Exome-Sequencing Project-European American samples, n = 4300 samples
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